Compare Inovio Pharmaceuticals Inc (INO) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Kimberly Clark Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Kimberly Clark Corp trades at $108.46 (market cap $36.11B). The key difference: Kimberly Clark Corp is far larger — about 459.7× Inovio Pharmaceuticals Inc's market cap, and Kimberly Clark Corp pays a 4.72% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | KMB | |
|---|---|---|
Market Cap | $78.55M | $36.11B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $134.81 |
52-Week Low | $0.66 | $93.05 |
Enterprise Value | $49.56M | $41.67B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Kimberly-Clark (KMB) trades at $108.95, up 0.86% on the day, with a neutral technical signal. The stock shows strong profitability with a net income margin of 11.79% and a high ROE of 129.43%, though revenue declined to $16.45B in 2025. Recent Q2 2026 earnings missed expectations, and the company cut its 2026 outlook due to challenges in China and softer consumer demand, as reported by Reuters on August 4, 2026.
The outlook is mixed; KMB offers a solid dividend yield and trades below the consensus price target of $113.20, but near-term headwinds from China and volatile shipments pose risks. Analyst sentiment is cautious with 61.29% hold ratings, reflecting balanced optimism for long-term value against short-term operational pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
